Economic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective
{{output}}
Background: CAR-T cell (chimeric antigen receptor T) therapy is now part of standard of care treatment of B‑cell lineage malignancies. Although it is an effective treatment, it comes along with adverse side effects and toxicitie... ...
